Search

Your search keyword '"Rautela, J."' showing total 100 results

Search Constraints

Start Over You searched for: Author "Rautela, J." Remove constraint Author: "Rautela, J."
100 results on '"Rautela, J."'

Search Results

2. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy

Catalog

Books, media, physical & digital resources

5. BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia

6. Mesenchymal stromal cell apoptosis is required for their therapeutic function

10. NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS (vol 217, e20191421, 2020)

11. NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS

12. Drug target validation in primary human natural killer cells using CRISPR RNP

13. Hhex Directly Represses BIM-Dependent Apoptosis to Promote NK Cell Development and Maintenance

14. NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS

16. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of ikaros and aiolos.

17. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

18. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC

19. Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions

20. The immunomodulatory drugs, through loss of Ikaros and Aiolos, derepress CD38 and functionally synergise with daratumumab.

21. GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function

22. Molecular insight into targeting the NK cell immune response to cancer

23. Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion

24. Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival

25. Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer

26. Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer

27. S-20

36. Soluble CD52 mediates immune suppression by human seminal fluid.

37. Optimisation of a primary human CAR-NK cell manufacturing pipeline.

39. IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.

40. Author Correction: CIS is a potent checkpoint in NK cell-mediated tumor immunity.

41. CD45 limits early Natural Killer cell development.

42. CIS controls the functional polarization of GM-CSF-derived macrophages.

43. An Augmented Method for Collecting PLGA Nanoparticles and the Fabrication of 1, 3, 4, 6-Tetra- O -acetyl-2-azido-2-deoxy-D-glucopyranose (Ac 4 2AzGlc)-Loaded PLGA Nanoparticles for Efficient and Prospective in Vivo Metabolic Processing.

44. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy.

45. Mesenchymal stromal cell apoptosis is required for their therapeutic function.

46. Differential requirement for the Polycomb repressor complex 2 in dendritic cell and tissue-resident myeloid cell homeostasis.

47. BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia.

48. Single-cell analyses reveal the clonal and molecular aetiology of Flt3L-induced emergency dendritic cell development.

49. Hhex Directly Represses BIM-Dependent Apoptosis to Promote NK Cell Development and Maintenance.

50. Drug target validation in primary human natural killer cells using CRISPR RNP.